Evidence map›Paper›PMID 41300833›Full record

ArticleGenes2025

Ruyu Bai, Zhiyun Cheng, Yong Diao

Abstract read
In one paragraph

Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Bioinformatics Analysis of the Diagnostic Value of Copper and Zinc Metabolism-Related Genes in Major Depressive Disorder: An In Silico Multi-Cohort Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ruyu BaiSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Zhiyun ChengSchool of Medicine, Huaqiao University, Quanzhou 362021, China.
Yong DiaoSchool of Medicine, Huaqiao University, Quanzhou 362021, China.ORCID 0000-0002-0633-1906

Funding

High level Talent Innovation and Entrepreneurship Project of Quanzhou 2022C006Rthe major and Special Projects of Fujian Province 2020NZ010008
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a progressive neurodegenerative disorder with unclear pathogenic mechanisms. Dysregulated zinc metabolism contributes to AD pathology. This study aimed to identify zinc metabolism-related hub genes to provide potential biomarkers and therapeutic targets for AD.

methodsWe performed an integrative analysis of multiple transcriptomic datasets from AD patients and normal controls. Differentially expressed genes and weighted gene co-expression network analysis (WGCNA) were combined to identify hub genes. We then conducted Gene Set Enrichment Analysis (GSEA), immune cell infiltration analysis (CIBERSORT), and receiver operating characteristic (ROC) curve analysis to assess the hub gene's biological function, immune context, and diagnostic performance. Drug-gene interactions were predicted using the DrugBank database.

resultsWe identified a single key zinc transporter-related hub gene,

conclusionsOur study systematically identifies

Indexed as

Alzheimer DiseaseCation Transport ProteinsZincBiomarkersGene Expression ProfilingGene Regulatory NetworksHumansTranscriptomeBiomarkersCation Transport ProteinsSLC30A3 protein, humanZincAlzheimer’s diseasebiomarkerSLC30A3therapeutic targetzinc metabolism-related genes

Identifiers

PMID41300833
PMCPMC12651988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.